ESR1 and invasive breast carcinoma: The pathology database search identified that ER IHC was performed on 3786 cases of invasive breast carcinomas following the updated 2010 ASCO/CAP guidelines, 40 (1.05%) of which were reported as demonstrating low (1–10%) ER expression.